Search results
Showing 421 to 435 of 661 results for diabetes
This quality standard covers assessing and managing bedwetting (nocturnal enuresis) in children and young people (aged 18 and under). It describes high-quality care in priority areas for improvement.
View quality statements for QS70Show all sections
This guidance has been updated and replaced by NICE guideline NG28.
This quality standard covers the care of pregnant women or pregnant people who are considering having or may need to have a caesarean birth, including those who have had a caesarean birth in the past. It includes decision making, reducing the risk of complications and care after a caesarean birth. It describes high-quality care in priority areas for improvement.
View quality statements for QS32Show all sections
Sections for QS32
- Quality statements
- Quality statement 1: Vaginal birth after a caesarean birth
- Quality statement 2: Request for a caesarean birth: maternity team involvement
- Quality statement 3: Request for a caesarean birth: anxiety
- Quality statement 4: Consultant obstetrician involvement in decision making for planned caesarean birth
- Quality statement 5: Timing of planned caesarean birth
- Quality statement 6: Consultant obstetrician involvement in decision making for unplanned caesarean birth
- Quality statement 7: The use of fetal blood sampling
Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome (HST31)
Evidence-based recommendations on setmelanotide (Imcivree) for treating obesity and hyperphagia in Bardet-Biedl syndrome in people 6 years and over, only if they are between 6 and 17 years when treatment starts.
NICE has developed a medtech innovation briefing (MIB) on DuraGraft for preserving vascular grafts .
This guideline covers the recognition, diagnosis and early management of suspected sepsis in pregnant or recently pregnant people. It includes recommendations on recognition and early assessment, initial treatment, escalating care, finding and controlling the source of infection, early monitoring, information and support, and training and education.
Recent-onset chest pain of suspected cardiac origin: assessment and diagnosis (CG95)
This guideline covers assessing and diagnosing recent chest pain in people aged 18 and over and managing symptoms while a diagnosis is being made. It aims to improve outcomes by providing advice on tests (ECG, high-sensitivity troponin tests, multislice CT angiography, functional testing) that support healthcare professionals to make a speedy and accurate diagnosis.
This guideline covers changing health-damaging behaviours among people aged 16 and over using interventions such as goals and planning, feedback and monitoring, and social support. It aims to help tackle a range of behaviours including alcohol misuse, poor eating patterns, lack of physical activity, unsafe sexual behaviour and smoking.
NICE has developed a medtech innovation briefing (MIB) on LQD Spray for treating acute and chronic wounds .
Woundchek Protease Status for assessing elevated protease status in chronic wounds (MIB83)
NICE has developed a medtech innovation briefing (MIB) on the Woundchek Protease Status for assessing elevated protease status in chronic wounds .
Cardiovascular risk assessment and lipid modification (QS100)
This quality standard covers identifying and assessing cardiovascular risk in adults without cardiovascular disease, and treatment to prevent primary and secondary cardiovascular disease. It describes high-quality care in priority areas for improvement.
View quality statements for QS100Show all sections
Sections for QS100
- Quality statements
- Quality statement 1: Identifying adults who are likely to be at high risk
- Quality statement 2: Diet and lifestyle advice for primary prevention
- Quality statement 3: Lipid-lowering treatment for primary prevention
- Quality statement 4: Assessing response to lipid-lowering treatment
- Quality statement 5: Secondary prevention of cardiovascular disease
- Update information
- About this quality standard
Read the biographies of our medical technologies advisory committee members.
Read the biographies of our medical technologies advisory committee members.
The Juxta CURES adjustable compression system for treating venous leg ulcers (MIB25)
NICE has developed a medtech innovation briefing (MIB) on the Juxta CURES adjustable compression system for treating venous leg ulcers
ClearWay RX for drug delivery to coronary artery thrombotic lesions (MIB55)
NICE has developed a medtech innovation briefing (MIB) on ClearWay RX for drug delivery to coronary artery thrombotic lesions